The rise of Viagra and its impact on the medicinal landscape presents a complicated question for shareholders. While the initial sales figures were astounding, the patent has lapsed, leading to a flood of generic alternatives that are eroding revenue. In addition, the sector is facing issues related to population trends and evolving healthcare guid